Perspective Therapeutics Files 8-K on Officer/Director Changes
Ticker: CATX · Form: 8-K · Filed: May 31, 2024 · CIK: 728387
Sentiment: neutral
Topics: leadership-change, governance, officer-compensation
TL;DR
Perspective Therapeutics 8-K: Leadership changes, officer compensation, and shareholder votes filed May 31.
AI Summary
Perspective Therapeutics, Inc. filed an 8-K on May 31, 2024, reporting on several key events. These include the departure of directors or certain officers, the election of directors, the appointment of certain officers, and details on compensatory arrangements for these officers. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and governance structure, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can signal shifts in company strategy or internal dynamics that may affect future performance.
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
FAQ
What specific officer or director positions were affected by the changes reported in the 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not specify individual names or positions within this summary.
Were there any specific compensatory arrangements detailed for the newly appointed or departing officers?
The 8-K mentions 'Compensatory Arrangements of Certain Officers' as an item covered, but the specific details of these arrangements are not provided in the summary.
What matters were submitted to a vote of security holders, as mentioned in the filing?
The filing states that 'Submission of Matters to a Vote of Security Holders' is an item reported, but the nature of these matters is not specified.
Does the 8-K filing include updated financial statements?
Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item being reported.
What is the company's former name and when did the name change occur?
The company was formerly known as Isoray, Inc. (or IsoRay, Inc.) and the date of name change was December 31, 2018.
Filing Stats: 1,031 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2024-05-31 16:05:12
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
Filing Documents
- catx-20240531.htm (8-K) — 67KB
- catx-ex10_1.htm (EX-10.1) — 171KB
- 0000950170-24-067300.txt ( ) — 376KB
- catx-20240531.xsd (EX-101.SCH) — 23KB
- catx-20240531_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 31, 2024, the Company held the Annual Meeting. Of the 586,915,977 shares of common stock outstanding and entitled to vote at the Annual Meeting, 363,330,450 shares (or 61.9%) were represented, either in person or by proxy, constituting a quorum. The following is a summary of the matters voted on at the Annual Meeting and the final voting results. Proposal One – The Election Proposal . The stockholders of the Company elected Lori A. Woods, Heidi Henson, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor and Robert Froman Williamson, III to the Board to hold office until the Company's 2025 Annual Meeting of Stockholders and until his or her successor has been elected and qualified. The votes were cast as follows: For Withheld Broker Non-Votes Lori A. Woods 187,149,965 100,985,018 75,195,467 Heidi Henson 280,096,242 8,038,741 75,195,467 Frank Morich, M.D., Ph.D. 244,896,693 43,238,290 75,195,467 Johan (Thijs) Spoor 285,624,604 2,510,379 75,195,467 Robert Froman Williamson, III 267,300,458 20,834,525 75,195,467 Proposal Two – The Reverse Stock Split Proposal . The stockholders of the Company approved the proposal to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1:10 (the "Reverse Stock Split"), with the Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. The votes were cast as follows: For Against Abstain Broker Non-Votes 255,843,194 106,316,349 1,170,907 - Proposal Three – The Auditor Ratification Proposal . The stockholders of the Company ratified the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: For Against Abst
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: May 31, 2024 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer